Karin Neukam-rekin lankidetzan egindako argitalpenak (16)

2014

  1. A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers

    Liver International, Vol. 34, Núm. 4, pp. 558-566

  2. Association of low-density lipoprotein receptor genotypes with hepatitis C viral load

    Genes and Immunity, Vol. 15, Núm. 1, pp. 16-24

  3. IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians

    PLoS ONE, Vol. 9, Núm. 4

  4. Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy

    Journal of Infection, Vol. 68, Núm. 4, pp. 372-377

2013

  1. A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 4, pp. 915-921

  2. Chronic hepatitis e in HIV patients: Rapid progression to cirrhosis and response to oral ribavirin

    Clinical Infectious Diseases, Vol. 57, Núm. 3, pp. 465-468

  3. Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 32, Núm. 11, pp. 1427-1435

  4. Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves

    Journal of Medical Virology, Vol. 85, Núm. 10, pp. 1734-1740

  5. Pegylated interferon plus ribavirin is suboptimal inIL28B CC carriers without rapid response

    Journal of Infection, Vol. 67, Núm. 1, pp. 59-64

  6. Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection

    AIDS, Vol. 27, Núm. 17, pp. 2715-2724

2012

  1. Differences in virological response to peginterferon-a plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b

    Journal of Acquired Immune Deficiency Syndromes, Vol. 60, Núm. 2, pp. 117-123

  2. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load

    Journal of Hepatology, Vol. 56, Núm. 4, pp. 788-794

2011

  1. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype

    HIV Medicine, Vol. 12, Núm. 8, pp. 487-493

  2. Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonresponse or relapse

    AIDS, Vol. 25, Núm. 8, pp. 1131-1133

  3. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy

    Journal of Infectious Diseases, Vol. 203, Núm. 11, pp. 1629-1636

2010

  1. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV

    Clinical Infectious Diseases, Vol. 51, Núm. 10, pp. 1209-1216